Cancer Research UK Center for Drug Development
Clinical research activity is centred on metastatic pancreatic ductal adenocarcinoma, with interest in the treatment of advanced pancreatic cancer and tumour control in late-stage disease.
- Metastatic pancreatic ductal adenocarcinoma
- Advanced pancreatic cancer
- Anticancer therapy
Research focuses on combination treatment strategies involving gemcitabine, nab-paclitaxel, and maintenance use of cobimetinib alongside an investigational monoclonal antibody.
Oncology and tumour response assessment
The sponsor’s funded trial activity is directed toward solid tumour treatment, with attention to anti-tumour activity, disease stabilisation, and response in pancreatic malignancy.
- Solid tumours
- Anti-tumour activity
- Disease stabilisation
Clinical interest includes treatment settings after initial disease control and the use of targeted combinations in maintenance therapy.
Targeted therapy and combination regimens
Research activity extends to combination approaches pairing an investigational agent with chemotherapy and signal transduction inhibition in pancreatic ductal adenocarcinoma.
- Combination therapy
- Chemotherapy
- Signal transduction inhibition
These studies reflect therapeutic interest in integrating targeted agents with established first-line treatment and subsequent maintenance treatment.
Safety and tolerability in cancer treatment
Funded research includes evaluation of safety, toxicity, and treatment tolerability in patients receiving multi-agent therapy for advanced pancreatic cancer.
- Safety profile
- Toxicity
- Tolerability
Clinical interest is focused on identifying treatment options suitable for patients with ongoing response or stable disease after standard therapy.
